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Control system development for Coline 6 linear accelerator 
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Purpose/Objective: The purpose of this study was to verify safety 
interlocks consistent with international standards IEC 60601-2-1 using 
a linear accelerator Coline 6 control system developed through the 
European Accelerators & Detectors AiD Project (AiD project: 
Development of dedicated systems based on accelerators and 
detectors of ionizing radiation for medical therapy and indetection of 
hazardous materials and toxic wastes) in The Polish National Centre 
for Nuclear Research. 
Materials and Methods: The pre-prototype of the control system 
works with the registration and verification software developed in the 
National Centre for Nuclear Research and Treatment Planning System 
PHJ Prague.The system analysis was performed to assess the security 
operation responsible for the dose off including verifications of error 
messages of measurement doses related to dosimetry measurement 
devices, mechanical failure of accelerator elements and use by an 
unauthorized user. Before starting the irradiations various cases 
ofoperator errors, omissions in remote data retrieval therapy and 
manual dialing parameters were tested. During the irradiations 
different schedules of dose measurements device and accelerator 
mechanical device errors were tested. 
Results: Safety of the patient during the irradiation is dependent on 
the manufacturer of the treatment devices. The accelerator control 
system was designed to meet all treatment parameters obtained from 
the Treatment Planning System and terminated irradiation if the 
parameters were inconsistent with the plan. The pre-prototype of the 
control system met all requirements. 
Conclusions: The analysis of the cases used in this study showed that 
the control system created as a pre-prototype can be the first step to 
create clinically acceptable software. 
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Purpose/Objective: The importance in local control and toxicity of 
optimal applicator placement in cervical cancer brachytherapy (BT) is 
well established. Nevertheless uterine perforation remains a frequent 
complication, generally undetected by classic QA measures of 2D BT 
to assess the adequacy of implant placement. 3D BT based on CT 
imaging allows optimal visualization of applicator’s position in respect 
to the OARs thus enabling the possibility of dose optimization. Aim of 
this work is to define the dosimetric impact on OARs of undetected 
uterine perforation when a standard point A optimized dose 
distribution is applied and the eventual dosimetric gain achievable 
with 3D CT-based dose optimization. 
Materials and Methods: 23 CT-based tandem/ovoids BT applications 
complicated by uterine perforation were selected. All patients had a 
FIGO IIB cervical cancer and were planned to receive radio-
chemotherapy (1.8 Gy per fraction up to 45 Gy with concomitant 
weekly cisplatin) and BT (4 fractions of 7 Gy) with a plan optimized to 
HRCTV drawn according clinical findings at the time of BT. The 
planning aim for dose optimization was to keep the D2cc value for 
rectum, bladder and sigmoid below 4.6 Gy, 6.5 Gy and 4.6 Gy 
respectively. Moreover a standard point A plan was calculated and 
respective DVH parameters for HRCTVs and OARs compared. Wilcoxon 
test was applied for statistical data analysis and calculated with 
Matlab 7.11 software (Mathworks Inc). 
Results: Median HRCTV width was 46 mm (37-64 range). Median 
HRCTV D90 and OAR D2cc values achieved with standard or the 
optimized plan are listed in table 1. When the standard plan was 
applied the intended dosimetric constraint for rectum, bladder and 
sigmoid were not achieved in 15 (60%), 10 (43,5%) and 19 (82%) 
applications respectively while they were always met in the 3D 
optimized plans. In 8 out of the 19 standard plans where the 
dosimetric constraint was exceeded the sigmoid D2cc was higher than 
8Gy. In 3 cases out of 19 it was higher than10Gy. 
 
*p-value < 0,001 Standard plan Optimized plan 
HRCTV D90 (Gy) * 7,5 (range 6 – 10,1) 6,4 (range 4,8 – 9,6) 
Rectum D2cc (Gy) * 5,2 (range 2,33 - 6,73) 4,5 (range 2,68 – 4,71) 
Bladder D2cc (Gy) 6,3 (range 3,8 - 17,6) 6,1 (range 4,34 – 6,4) 
Sigmoid D2cc (Gy)* 6,8 (range 1,78 – 16,75) 2,9 (range 0,8 – 4,65) 
 
Conclusions: The occurrence of uterine perforation should be kept as 
low as possible by the routine use of US during GYN BT implantation. 
When uterine perforation occurs it is easily detected on CT images but 
rarely on the orthogonal films. In case of uterine perforation 2D 
planning may thus results in potentially dangerous over dosage of 
OARs. 3D optimization allows keeping OAR dose within tolerance 
constraints just minimally compromising HRCTV D90 coverage.  
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Purpose/Objective: To evaluate if glycosaminoglycan’s (GAG) 
administration as hyaluronicacid (HA) intravesical instillations reduces 
the rate of acute and lateradio induced bladder toxicity as a 
complication of radiation treatment in gynecological cancer. A review 
of the literature was done to analyse which treatments were used in 
this field and the HA role among them. 
Materials and Methods: Retrospective study of 70 patients diagnosed 
with cervical and endometrial cancer treated between May 2010 and 
June 2012 with high-dose rate brachytherapy (HDR-BT) with or 
without external beam radiotherapy (EBRT). 50/70 received an EBRT 
total dose of 45-50.4 Gy delivered in 25-28 fractions followed by 
brachytherapy (HDR-BT) 11Gy in 2 fractions. The remaining 20 
patients received HDR-BT alone, 21 Gy in 3 fractions. All of them 
received intravesical instillations of hyaluronic acid (HA) immediately 
after each HDR-BT fraction according to recommendations of medical 
prospectus. 5/50 (10%) presented G1-2 toxicity before brachytherapy. 
RTOG/EORTC scale was used to evaluate acute and late toxicity rates 
at 3, 6, 12 and 18 months after HDR-BT. A review of the literature was 
made using Medline research with the following criteria: HA 
prevention and gynecological cancer and radioinduced cystitis. 
Results: Regarding our study, no upgrading toxicity was observed in 
patients treated with combined HDR-BT and EBRT (50/70) during the 
follow-up period. None of the patients (20/70) treated with exclusive 
HDR-BT had bladder toxicity neither acute nor chronic. No adverse 
events related to HA were observed. After reviewing literature, we 
observed that HA instillations have demonstrated effectiveness in 
relieving symptoms associated with interstitial cystitis, considering a 
similar biological pattern to radioinduced cystitis. 2 studies with these 
characteristics and written by the same authors were found: P. 
Samper et al. The first one is an abstract presented at ASCO 2003 with 
90 patients and the other a retrospective study with 95 patients; both 
of them demonstrate that HA instillations are effective in 
radioinduced cystitis prevention.  
Conclusions: Intravesical instillations of hyaluronic acid are effective 
in preventing radiation cystitis. It is safe and well tolerated. Given the 
scarcity reports on this subject, it is difficult to draw any firm 
conclusions about standard recommendations. However, based on our 
experience, intravesical HA can be used as routine before each 
brachytherapy fraction in gynecological cancer. A prospective 
randomized control study with a large number of patients and long 
term follow-up is recommended. 
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Purpose/Objective: To compare complication rate, outcome, and 
compliance of patients (pts) treated with pulsed dose rate (PDR) 
versus low dose rate (LDR) brachytherapy (BRT) following external 
beam radiation therapy (EBRT) for endometrial cancer (EC). 
Materials and Methods: From August 2009 to August 2012, 50 
consecutive pts, undergoing total abdominal hysterectomy, bilateral 
salpingo-oophorectomy for endometrial cancer were treated by 
adjuvant EBRT and intra-cavitary PDR BRT because of invasion of the 
cervical canal. Median age was 68 years. Pathological stage according 
to the FIGO 2010 classification was: 7 IA, 9 IB, 21 II, 1 IIIA, 2 IIIB,9 IIIC, 
1 IVA. Histology was adenocarcinoma in 35 cases (70%) and other 
histologies in 15 cases (30%). All pts underwent EBRT to the pelvic 
region to a total dose of 45-50 Gy in 25 fractions, with a 3D-RT in 29 
cases (58%), and with IMRT in 21 cases (42%). After EBRT, all pts 
underwent to BRT boost with PDR 192Ir source. The median PDR dose 
(prescribed to 0.5 cm from the vaginal surface) was 9 Gy (1 
application/die delivered by means of 10 or 12 pulses of 0.45 Gy every 
half an hour for 2 days). A cohort of 44 pts with similar clinical 
characteristics and treated by LDR BRT from 1998 to 2006 was 
analyzed and compared. In the LDR group, median age was 67.5 years, 
pathological stage showed 7 IA, 11 IB, 17 II, 3 IIIA, 1 IIIB,5 IIIC and 
histology was adenocarcinoma in 39 cases (89%) and other histologies 
in 5 cases (11%). All pts after EBRT to the pelvic region to a total dose 
of 45-50 Gy in 25 fractions underwent BRT boost with LDR 137Cs 
sources inserted with a customized vaginal moulde (moulage). The 
median LDR dose (prescribed to 0.5 cm from the vaginal surface) was 
13 Gy (range, 10 -15 Gy). Acute and late effects were assessed by the 
RTOG scoring systems in both treatment groups.  
Results: Early toxicity as G1-G2 enteric, urinary and vaginal was 
observed in 14%, 16%, 38% of cases and in 41%, 16%, 36% of cases in 
the PDR and LDR group, respectively. G3 vaginal acute toxicity was 
found in 4% of pts only in PDR group. With a median follow-up of 17 
and 59 months for the PDR and LDR group,1 (2%) and 3 pts (6%) 
developed vaginal-cuff relapse, and 2 (4%) and 3 pts (7%) developed 
distance metastasis, respectively. Late toxicity as G1-2 gastro-enteric, 
urinary and vaginal was observed in 2%, 0%, 12% of cases and in 2%, 
2%, 15% of cases of the PDR and LDR group, respectively.No pts was 
excluded a priori from the both PDR and LDR treatment, and no pts 
interrupted both the PDR and LDR treatment. 
Conclusions: PDR BRT is a safe and effective BRT method in the 
treatment of EC. It combines the physics benefits of dose optimization 
and the radiobiological advantages of LDR BRT. PDR allowed also to 
avoid the exposure of personnel to ionizing radiation making easier 
the patient management. 
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Purpose/Objective: Due to its superior soft-tissue contrast, magnetic 
resonance imaging (MRI) is valuable in image guided interventions like 
brachytherapy (BT). It provides better visualization of the target and 
critical structures at the moment of intervention. At the UMC Utrecht 
we built a dedicated treatment suite equipped with an HDR 
afterloader and a 1.5 T MR scanner, where patient treatment and MRI 
can be combined. Purpose of this combined interventional imaging 
and application approach is to treat patients with 3D MRI guided 
adaptive brachytherapy and to control DVH parameters before start of 
irradiation. In this abstract we describe our first clinical experience 
with MR guided interstitial BT of the orbita/ nasal cavity area. 
Materials and Methods: This study decribes the MRI guided BT 
procedure for 2 patients. Patient 1 received pulsed dose rate (PDR) BT 
on the resection margins after exenteratio orbitae due to a acinic cell 
carcinoma of the lacrimal gland. Patient 2 recieved PDR BT after 
exenteratio orbitae for a local recurrence within 1.5 years of a 
squamous cell carcinoma originating from the oral cavity. Individual 
moulds were made that fitted the patients orbita cavity. Patients 
underwent MR imaging prior to BT. MRI based preplans were made to 
determine catheter trajectories for optimal dose distribution. 
Catheter trajectories were drilled into or glued to the mould and 
patients underwent MR imaging with mould in situ to verify the 
position of the catheters in relation to patients anatomy. The 
catheters were filled with saline solution to make them visible on MRI. 
Preplans were made with the catheter positions visible. Application of 
the mould and the catheters was performed in the MRI-HDR suite to 
verify the mould position and thereafter a definitive dose distribution 
was planned. For patient 1 twelve catheters were inserted up to 36 
mm into the tissue under MR guidance posterior in the orbitacavity. 
For patient 2 fourteen catheters were placed in the mould and 2 
catheters interstitially in the cheek. The accuracy of MRI based 
reconstruction was verified by CT based reconstruction. The following 
tumorcidal dose parameters were evaluated: V100, V150 and V200 
(percentage target volume receiving 100%, 150% and 200% of the 
prescription dose, respectively). 
Results: For both patients, the MRI guided BT procedure with mould 
was feasible and the reconstruction accuracy was ±1 mm. The 
prescription dose for patient 1 was 78 pulses of 70 cGy, given in 
extended office hours. V100= 97%, V150=61%, V200=22%. Short term 
follow up (8 months): no evidence of disease. The prescription dose 
for patient 2 was 82 pulsesof 70 cGy, given in extended office hours. 
V100= 82%, V150=37%, V200=19%. Short term follow up (9 months): no 
evidence ofdisease. 
Conclusions: MR guided interstitial BT with moulds is feasible and may 
lead to better positioning of catheters with respect to target volume 
and thus better dose distributions. 
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Purpose/Objective: To verify the accuracy of an independent point 
dose calculation to validate the dose calculation algorithm (AAPM TG-
43) of a brachytherapy treatment planning system. 
Materials and Methods: Commissioning was performed of the 
Nucletron Oncentra Brachytherapy (v 4.1) treatment planning system. 
The source configuration data of Nucletron 192-Ir-mHDR-V2 and other 
TG-43 parameters, including dose rate constant, geometry factor, 
radial dose function and anisotropy function, were checked for errors 
and anomalies. This data was also entered into RadCalc (v 6.1) 
software for use as an independent point dose calculation method, 
and a manual calculation of treatment time of three sources dwell 
position was compared to that reported by the Oncentra TPS. The 
point dose calculations based on the TG-43 dosimetry protocol were 
also compared to the previously commissioned Nucletron Plato (v 
14.3.7) brachytherapy TPS, and also verified using the brachytherapy 
module in RadCalc. Thirty-four retrospective treatment plans (25 
cervical CA using tandem and ovoids and 9 endometrium CA using 
cylinder and ovoids) were generated using Plato and Oncentra with 
the same planning data sets (normalization, optimization, and 
prescription dose). The plan results, source times and point doses, 
were compared with each system and also exported to RadCalc and 
evaluated using an acceptance criteria of ±2% for agreement. 
Results: The dose computation algorithm appears consistent to within 
less than 2% for Oncentra, Plato and Radcalc, in terms of point doses 
and source times. The total treatment time for Oncentra and Radcalc 
are equal for each patient plan. For Plato and Oncentra, the 
treatment times differ slightly due to differences in the rounding 
methods used to determine the dwell times for each source position. 
An independent, manual treatment time check was also found to be 
within acceptable limits of ±2% for a multiple-source (dwell position). 
Conclusions: The point dose verification for brachytherapy planning 
system was accepted for clinical use. Independent checks using point 
dose calculation software provide a simple, fast and accurate method 
to check TPS. Since patient-specific quality assurance requires a quick 
and simple method, this approach can be confidently used to verify 
the accuracy of dose calculation prior to each patient treatment.  
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TRUS-guided real-time prostate HDR brachytherapy treatment 
planning: dosimetry and learning curve  
